GenSight's Project Portfolio Management solution chosen by Integra Lifesciences, to enhance new product process
Naples, FL (PRWEB) February 16, 2016 -- GenSight, a leader in integrated software for new product and portfolio management, resource management, Stage-Gate®, and project management, announced today that Integra LifeSciences (“Integra”) has selected GenSight’s Software-as-a-Service solution to help it enhance its R&D processes related to the development of innovative new products.
Integra, a world leader in medical technology, recognized the need to implement an advanced technology solution to enable and integrate its portfolio management, resource management, and project management processes. After reviewing a number of PPM software vendors, Integra selected GenSight’s technology as the best tool to enhance the company’s project, portfolio and resource management processes to fuel innovation and growth.
JoAnne Harla, Integra’s Vice President, Global Program Management Leader said: “Integra chose GenSight because of its advanced enterprise capability in one integrated solution, and the ease of configuration and integration with the company’s existing business processes and data sources. The GenSight tool supports our aim to improve the efficiency of R&D by helping us better prioritize the most innovative and valuable initiatives, and allocate our resources optimally across the portfolio.”
GenSight provides management support to large corporations that have thousands of innovation, business, process, technology and capital investment programs. From idea to delivery, GenSight enables critical decision making on where to invest, which programs and projects to prioritize, and how to execute and bring those projects to value more quickly. GenSight’s optimizes resource allocation to accelerate successful product development, time-to-market, and value creation.
The latest version of its enterprise project portfolio management solution, GenSight v9.2, is highly scalable, provides a range of deployment options including Cloud, On-Premise and Hybrid, and comes fully-featured including dynamic HTML5 charts and graphics.
“The GenSight team is excited to work with an organization focused on driving continuous innovation, consumer value, and value for its stakeholders” said Michael Menard, President and Co-Founder of GenSight. “Integra has developed a very impressive portfolio management process, and we are proud Integra LifeSciences has selected GenSight’s technology to automate and enable this important part of its business to drive capital efficient profitable growth.”
About The GenSight Group
GenSight is the world’s leading Enterprise Portfolio Management solution today. It is the industry’s only complete platform for complex Portfolio Management, Resource Optimization, and Stage-Gate® Management. Our total solution integrates business process consulting, best-of-breed technology, and implementation methodology.
The Forrester Wave ™ recently highlighted GenSight as a leader for Portfolio Management and placed the company in the Leaders category. Just some of the organizations deploying the GenSight solution are Johnson and Johnson, Suncor Energy, Pfizer, Cisco, Natura, Westinghouse, Sun Chemical, GlaxoSmithKline and the US Department of Energy.
GenSight is an official participant of the United Nations Global Compact, enabling leading corporations around the globe to improve their fundamental ability to create a more sustainable future by optimizing the allocation of limited resource to generate the greatest good for the environment, shareholders and communities.
GENSIGHT: THE VALUE OF INSIGHT http://www.gensight.com
About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit http://www.integralife.com.
Samantha Huntington, GenSight, http://www.gensight.com, +1 239 300 3407, [email protected]
Share this article